ASCO expert panel chaired by Navneet Singh and Megan Daly has published an update on management of stage III NSCLC based on the ADAURA and KEYNOTE-671 trials – Navneet Singh
The American Society of Clinical Oncology (ASCO) expert panel chaired by Navneet Singh and Megan Daly and immensely supported by guidelines specialist Nofisat Ismaila, MD, MSc, PhD(c) has published an update on management of stage III NSCLC based on the ADAURA and KEYNOTE-671 trials presented at the ASCO Annual Meeting and also incorporated data from the CHECKMATE-816 trial. All 3 trials have been published in the NEJM Group Link to full text accessible at https://lnkd.in/dCkgySGB
The ADAURA trial assessed outcomes with adjuvant osimertinib for completely resected early stage NSCLC and harboring either of the two activating EGFR mutations (exon 19 deletion OR exon 21 L858R) while the CheckMate-816 and KEYNOTE-671 trials assessed efficacy of neoadjuvant immunotherapy (in combination with chemotherapy) for potentially resectable early stage NSCLC. These indicate integration of immunotherapy and targeted therapy (with chemotherapy) for management of non-metastatic disease (akin to what happened earlier for metastatic NSCLC).
Source: Navneet Singh/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023